These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 8553652)

  • 1. Hypocalcemia due to avid calcium uptake by osteoblastic metastases of prostate cancer.
    Szentirmai M; Constantinou C; Rainey JM; Loewenstein JE
    West J Med; 1995 Dec; 163(6):577-8. PubMed ID: 8553652
    [No Abstract]   [Full Text] [Related]  

  • 2. Severe hypocalcaemia associated with extensive osteoblastic metastases in a patient with prostate cancer.
    Fokkema MI; de Heide LJ; van Schelven WD; Hamdy NA
    Neth J Med; 2005 Jan; 63(1):34-7. PubMed ID: 15719851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of disordered calcium metabolism in hormone-refractory prostate cancer patients with metastatic bone disease.
    Tucci M; Mosca A; Lamanna G; Porpiglia F; Terzolo M; Vana F; Cracco C; Russo L; Gorzegno G; Tampellini M; Torta M; Reimondo G; Poggio M; Scarpa RM; Angeli A; Dogliotti L; Berruti A
    Prostate Cancer Prostatic Dis; 2009; 12(1):94-9. PubMed ID: 18332901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolonged hypocalcemia after zoledronic acid in a patient with metastatic prostate carcinoma: did zoledronic acid trigger osteoblastic activity and avid calcium uptake?
    Ho JW; Sundar S
    Clin Genitourin Cancer; 2012 Mar; 10(1):50-3. PubMed ID: 22245101
    [No Abstract]   [Full Text] [Related]  

  • 5. Zoledronic acid-induced severe hypocalcaemia in a prostate cancer patient with extensive osteoblastic bone metastases.
    Patel K; Brahmbhatt V; Ramu V
    Tenn Med; 2005 Feb; 98(2):83-5, 89. PubMed ID: 15779196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A man with osteoblastic metastasis and hypocalcaemia.
    Lim SC; Tan CE; Aw TC; Khoo D; Eng P; Ho SC; Tai ES; Fok A
    Singapore Med J; 2000 Feb; 41(2):74-6. PubMed ID: 11063207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severe hypocalcaemia because of osteoblastic prostate carcinoma metastases.
    Yener S; Demir O; Ozdogan O; Akinci B; Yesil S
    Int J Clin Pract; 2008 Oct; 62(10):1630-1. PubMed ID: 18822033
    [No Abstract]   [Full Text] [Related]  

  • 8. Metabolic studies in a case of hypocalcemia and osteoblastic metastases.
    Tommaso CL; Tucci JR
    Arch Intern Med; 1979 Feb; 139(2):238-41. PubMed ID: 219791
    [No Abstract]   [Full Text] [Related]  

  • 9. Prostate cancer bone metastases promote both osteolytic and osteoblastic activity.
    Keller ET; Brown J
    J Cell Biochem; 2004 Mar; 91(4):718-29. PubMed ID: 14991763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autoradiographic studies of rhenium-188-hydroxyethylidine diphosphonate in normal skeleton and osteoblastic bone metastases in a rat model of metastatic prostate cancer.
    Liepe K; Geidel HH; Bergmann R; Haase M; Runge R; Kotzerke J
    Nucl Med Commun; 2009 Sep; 30(9):693-9. PubMed ID: 19528873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tranilast inhibits hormone refractory prostate cancer cell proliferation and suppresses transforming growth factor beta1-associated osteoblastic changes.
    Izumi K; Mizokami A; Li YQ; Narimoto K; Sugimoto K; Kadono Y; Kitagawa Y; Konaka H; Koh E; Keller ET; Namiki M
    Prostate; 2009 Aug; 69(11):1222-34. PubMed ID: 19434660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Biphosphonates in the treatment of bone metastasis of prostatic cancer].
    Paule B; Cicco A
    Prog Urol; 2001 Dec; 11(6):1205-12. PubMed ID: 11859653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity.
    Kitagawa Y; Dai J; Zhang J; Keller JM; Nor J; Yao Z; Keller ET
    Cancer Res; 2005 Dec; 65(23):10921-9. PubMed ID: 16322239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe hypocalcemia due to osteoblastic metastasis of prostate cancer.
    Diéguez Felechosa M; Noval Menéndez J; Manjón Miguelez L
    Med Clin (Barc); 2017 Mar; 148(6):287-288. PubMed ID: 28118964
    [No Abstract]   [Full Text] [Related]  

  • 15. Hungry bone syndrome: persistent hypocalcemia related to osteoblastic bone metastases of prostate cancer.
    Riveros HA; Almodóvar LO; Danés CF; Domingo JP
    J Palliat Med; 2013 Dec; 16(12):1496-7. PubMed ID: 24160743
    [No Abstract]   [Full Text] [Related]  

  • 16. Prostate-specific antigen induces apoptosis of osteoclast precursors: potential role in osteoblastic bone metastases of prostate cancer.
    Goya M; Ishii G; Miyamoto S; Hasebe T; Nagai K; Yonou H; Hatano T; Ogawa Y; Ochiai A
    Prostate; 2006 Nov; 66(15):1573-84. PubMed ID: 16927388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolonged hypocalcemia after treatment with zoledronic acid in a patient with prostate cancer and vitamin D deficiency.
    Breen TL; Shane E
    J Clin Oncol; 2004 Apr; 22(8):1531-2. PubMed ID: 15084635
    [No Abstract]   [Full Text] [Related]  

  • 18. Does prostate-specific antigen contribute to bone metastases?
    Chirgwin JM; Guise TA
    Clin Cancer Res; 2006 Mar; 12(5):1395-7. PubMed ID: 16533760
    [No Abstract]   [Full Text] [Related]  

  • 19. Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism.
    Dai J; Keller J; Zhang J; Lu Y; Yao Z; Keller ET
    Cancer Res; 2005 Sep; 65(18):8274-85. PubMed ID: 16166304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tetany induced on separate occasions by administration of potassium and magnesium in a patient with hungry-bone syndrome.
    Navarro J; Oster JR; Gkonos PJ; Ruiz JP; Rhamy RK; Perez GO
    Miner Electrolyte Metab; 1991; 17(5):340-4. PubMed ID: 1819767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.